Dr. Arend on Personalized Medicine for Endometrial Cancer

Rebecca C. Arend, MD
Published: Thursday, Jun 08, 2017



Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses personalized medicine for patients with endometrial cancer.

According to Arend, there has been a personalized medicine initiative that does panel sequencing on recurrent tumors. It is known that if a patient has a somatic BRCA mutation, they can receive rucaparib (Rubraca). Additionally, if a patient’s tumor is microsatellite instability-high (MSI-H), immunotherapy is available.

In the future, more research is needed to have more tumors looking like the MSI-H tumors, in order for them to respond to immunotherapy, states Arend.
 


Rebecca C. Arend, MD, assistant professor, UAB School of Medicine, UAB Department of Obstetrics and Gynecology, UAB Comprehensive Cancer Center, discusses personalized medicine for patients with endometrial cancer.

According to Arend, there has been a personalized medicine initiative that does panel sequencing on recurrent tumors. It is known that if a patient has a somatic BRCA mutation, they can receive rucaparib (Rubraca). Additionally, if a patient’s tumor is microsatellite instability-high (MSI-H), immunotherapy is available.

In the future, more research is needed to have more tumors looking like the MSI-H tumors, in order for them to respond to immunotherapy, states Arend.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x